Table 2.
Phenotype of cells per patient
| Patient | Total infusion/patient | Average cell counts/infusion (×109) | Viability (%) | Phenotype of cell product | Best response | Survival time | Outcome | |||
|---|---|---|---|---|---|---|---|---|---|---|
| CD3 (%) | CD8 (%) | CD56 (%) | PFS (weeks) | OS (weeks) | ||||||
| 1 | 8 | 69 | 97.2 | 97.7 | 93.8 | 13.9 | PD | 12.7 | 22.6 | Dead |
| 2 | 7 | 44.5 | 98 | 99.3 | 83.2 | 28.7 | PD | 11.9 | 20.6 | Dead |
| 3 | 7 | 58.5 | 98.2 | 99.4 | 88.2 | 20.1 | PD | 10.6 | 54.1 | Dead |
| 4 | 10 | 95.8 | 96.8 | 96.8 | 92.3 | 47.2 | SD | 18.9 | 84.9 | Dead |
| 5 | 7 | 55.2 | 97.6 | 98.5 | 87.4 | 18.5 | PD | 11.0 | 26.6 | Dead |
| 6 | 10 | 59.3 | 97.6 | 96.4 | 82.3 | 28.5 | SD | 22.3 | 52.9 | Dead |
| 7 | 10 | 68.2 | 97.5 | 98.2 | 86.1 | 22.3 | SD | 91.7 | 104.3 | Dead |
| 8 | 8 | 62.2 | 97.6 | 97 | 91 | 11.8 | PD | 13.4 | 71.0 | Dead |
| 9 | 7 | 45.5 | 97.2 | 99.1 | 89.8 | 27.5 | PD | 11.7 | 15.0 | Dead |
| 10 | 7 | 42.3 | 98.4 | 99.9 | 92 | 38.4 | PD | 10.6 | 39.6 | Dead |
| 11 | 7 | 46.6 | 97.7 | 99.6 | 80.4 | 36.9 | PD | 9.7 | 26.1 | Dead |
| 12 | 7 | 37.7 | 98 | 99.2 | 90.1 | 16.7 | PD | 10.0 | 35.3 | Dead |
| 13 | 7 | 42.9 | 98.4 | 99.5 | 90.1 | 19.2 | PD | 10.0 | 20.4 | Dead |
| 14 | 10 | 48.2 | 97.9 | 99.2 | 87.7 | 19.3 | SD | 14.3 | 19.3 | Dead |
| 15 | 8 | 40.2 | 97.5 | 99.5 | 72.9 | 21.4 | PD | 10.3 | 17.3 | Dead |
| 16 | 8 | 41.9 | 98.5 | 99.7 | 72.2 | 15.3 | PD | 10.1 | 65.4 | Dead |
PFS progression-free survival, OS overall survival, PD progress disease, SD stable disease